Antitumor activity against human MV411 cells xenografted in nude mouse assessed as tumor growth inhibition at 50 mg/kg, po administered qd for 21 days relative to vehicle treated control
Antitumor activity against human MV411 cells xenografted in nude mouse assessed as tumor growth inhibition at 100 mg/kg, po administered qd for 21 days relative to vehicle treated control
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor regression at 20 mg/kg, ip administered qd for 21 days measured after 2 to 3 days of last dose by hematoxylin staining
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor growth regression at 100 mg/kg, ip once daily for 21 days measured every 3 days
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 20 mg/kg, ip once daily for 21 days measured every 3 days
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 40 mg/kg, ip once daily for 21 days measured every 3 days
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor mitotic index at 20 mg/kg, ip administered qd for 21 days measured after 2 to 3 days of last dose by Ki67 staining-based immunohistochemical analysis
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as increase in apoptotic cells at 20 mg/kg, ip administered qd for 21 days measured after 2 to 3 days of last dose by TUNEL analysis
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 100 mg/kg, ip once daily for 21 days measured every 3 days relative to control
Antitumor activity against human MV4-11 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 50 mg/kg, ip once daily for 21 days measured every 3 days